Biodol Therapeutics is aiming to ease the burden of chronic pain for millions of patients around the globe. The company is developing a unique new drug with a dual function: a non-opioid standalone treatment for neuropathic pain or migraine, but also a combination therapy with opioids. By reversing opioid tolerance, Biodol’s compound eliminates the need for higher doses, making these powerful drugs safer and more effective at alleviating suffering.
• Fund+ portfolio company Tubulis will be acquired by Gilead for an upfront payment of USD 3.15 billion, with up to USD 1.85 billion in additional milestone payments
• Tubulis’ next-generation ADC platform includes its clinically validated linker-payload technology
• The acquisition includes Tubulis’ lead asset TUB-040, a NaPi2b-targeting ADC for ovarian cancer and other solid tumors
With the rapid rise of Chinese biopharma, this ‘new kid on the block’ has gone from baby to behemoth on the world stage. This powerhouse of innovation and industry is now turning heads in both the US and Europe, having transformed from copycat to top dog in the space of just a few years. How has China done it, and what can Europe do in response?
The most visible — yet often overlooked — parts of an innovative ecosystem are the buildings that house research and development activities. Far more than just office space, these physical foundations facilitate the translation of lofty ideas into tangible solutions for society. Kadans Science Partner is one of Europe’s foremost providers of this specialized infrastructure, with a unique community-minded model.
BioVox spoke with Sara Van Overmeire and Annie Renders of Flanders Innovation & Entrepreneurship (VLAIO) about the origin and role of spearhead clusters. VLAIO is the Flemish government’s point of contact for all entrepreneurs in Flanders. It relies on Biovia and other spearhead clusters to bring companies together and support them in setting up innovative projects.
Venture investing in early-stage companies hinges on spotting transformative technologies before they become hyped. To support this, we built the MeSH Counter: an R-based tool that tracks monthly frequencies of specific terms in PubMed, allowing us to visualize trends in the life sciences. Publication trends are not the same as investment signals, yet the MeSH Counter can help efficiently map the research landscape, so investors can prioritize deeper, human-led diligence.
Just weeks after announcing its plans for a U.S. listing, Belgium-based Agomab Therapeutics has gone public on Nasdaq, pricing its IPO at $16 per share to raise about $200 million. The stock is now trading under the ticker AGMB, putting the spotlight on fibrosis in what has been a billion-dollar week for biotech IPOs.
On 29 January 2026, 400 Belgian healthcare stakeholders — hospital executives, policymakers, and innovators — gathered in Brussels to help shape the future of healthcare. The objective was to connect hospital needs with the innovative technologies developed by Belgian companies. Two projects were honored during the event’s Innovation Awards: Baby Detect and SIM BLOOD.
We are all familiar with global viruses: The flu shows up every year across the world, and not long ago we collectively experienced the SARS-CoV-2 pandemic. Now, a neglected tropical disease is joining this club of viruses without borders. Dengue — also known as break-bone fever — is currently one of the world’s fastest spreading viral diseases, with more than half of the global population already at risk.
Early-stage biotech investing has always demanded a high tolerance for uncertainty, and an uncanny ability to predict which fledgling technologies will one day reshape health. But one silent force shapes investment outcomes more often than we admit: psychology. At the intersection of capital and culture, we find a compelling and underexplored story — the differences between investors in the US and Europe, and how these contrasts play out in biotech.
Biodol Therapeutics is aiming to ease the burden of chronic pain for millions of patients around the globe. The company is developing a unique new drug with a dual function: a non-opioid standalone treatment for neuropathic pain or migraine, but also a combination therapy with opioids. By reversing opioid tolerance, Biodol’s compound eliminates the need for higher doses, making these powerful drugs safer and more effective at alleviating suffering.
• Fund+ portfolio company Tubulis will be acquired by Gilead for an upfront payment of USD 3.15 billion, with up to USD 1.85 billion in additional milestone payments
• Tubulis’ next-generation ADC platform includes its clinically validated linker-payload technology
• The acquisition includes Tubulis’ lead asset TUB-040, a NaPi2b-targeting ADC for ovarian cancer and other solid tumors
With the rapid rise of Chinese biopharma, this ‘new kid on the block’ has gone from baby to behemoth on the world stage. This powerhouse of innovation and industry is now turning heads in both the US and Europe, having transformed from copycat to top dog in the space of just a few years. How has China done it, and what can Europe do in response?
The most visible — yet often overlooked — parts of an innovative ecosystem are the buildings that house research and development activities. Far more than just office space, these physical foundations facilitate the translation of lofty ideas into tangible solutions for society. Kadans Science Partner is one of Europe’s foremost providers of this specialized infrastructure, with a unique community-minded model.
BioVox spoke with Sara Van Overmeire and Annie Renders of Flanders Innovation & Entrepreneurship (VLAIO) about the origin and role of spearhead clusters. VLAIO is the Flemish government’s point of contact for all entrepreneurs in Flanders. It relies on Biovia and other spearhead clusters to bring companies together and support them in setting up innovative projects.
Venture investing in early-stage companies hinges on spotting transformative technologies before they become hyped. To support this, we built the MeSH Counter: an R-based tool that tracks monthly frequencies of specific terms in PubMed, allowing us to visualize trends in the life sciences. Publication trends are not the same as investment signals, yet the MeSH Counter can help efficiently map the research landscape, so investors can prioritize deeper, human-led diligence.
Just weeks after announcing its plans for a U.S. listing, Belgium-based Agomab Therapeutics has gone public on Nasdaq, pricing its IPO at $16 per share to raise about $200 million. The stock is now trading under the ticker AGMB, putting the spotlight on fibrosis in what has been a billion-dollar week for biotech IPOs.
On 29 January 2026, 400 Belgian healthcare stakeholders — hospital executives, policymakers, and innovators — gathered in Brussels to help shape the future of healthcare. The objective was to connect hospital needs with the innovative technologies developed by Belgian companies. Two projects were honored during the event’s Innovation Awards: Baby Detect and SIM BLOOD.
We are all familiar with global viruses: The flu shows up every year across the world, and not long ago we collectively experienced the SARS-CoV-2 pandemic. Now, a neglected tropical disease is joining this club of viruses without borders. Dengue — also known as break-bone fever — is currently one of the world’s fastest spreading viral diseases, with more than half of the global population already at risk.
Early-stage biotech investing has always demanded a high tolerance for uncertainty, and an uncanny ability to predict which fledgling technologies will one day reshape health. But one silent force shapes investment outcomes more often than we admit: psychology. At the intersection of capital and culture, we find a compelling and underexplored story — the differences between investors in the US and Europe, and how these contrasts play out in biotech.